SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (9508)1/30/2003 7:00:37 AM
From: Icebrg  Read Replies (1) of 9719
 
Stefaan

I doubt that should effect the valuation of Millennium as investors should already more or less have written off MLN02 for that indication. From MLNM September 16 PR:

"Although we are disappointed by not having met the primary endpoint, we are encouraged by the preliminary remission and safety results seen in this study and are hopeful that MLN02 has potential as an important treatment option for Crohn's patients," said John Maraganore, Ph.D., senior vice president, strategic product development at Millennium Pharmaceuticals. "We're looking forward to seeing the results of the phase II ulcerative colitis study , and contin uing to further refine the dose and clinical development plan for MLN02."

I would rather look at MLN02 as a part of the potential upside, as far as MLNM is concerned. If Antegren works MLN02 should also do so for the two IBD-indications, where it is tested.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News